Colorectal cancer (CRC) is one of the most common and deadliest forms of cancer worldwide. Molecular subgroups are increasingly relevant for prognosis and therapy. In addition to established markers such as RAS, BRAF and MSI, HER2 is also coming into focus as a therapeutic target. Particularly rare histological variants such as invasive micropapillary carcinoma (IMPC) raise new questions. A recent case report from Japan describes for the first time a patient with HER2-positive colorectal carcinoma and a micropapillary component. This article summarizes the available data and discusses the clinical significance of this constellation.
Autoren
- Tanja Schliebe
Publikation
- InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
You May Also Like
- Across All Types of Cancer
Four-Legged Medical Assistants – Therapy Dogs in Clinical Settings
- Obesity: More than half of those affected have fatty liver disease
From screening to multimodal intervention with GLP-1-RA or resmetirom
- Innovative Oral Treatment Options for Psoriasis: Icotrokinra and Zasocitinib
First-class immunomodulation combined with convenience—the data available so far is convincing
- Preclinical Study on a Special Ginkgo biloba Extract
What role do proanthocyanidins play?
- Myasthenia gravis: immunomodulatory therapies for long-term treatment
Expanded Possibilities Thanks to Innovative Classes of Active Ingredients
- Plastic surgery and reconstructive microsurgery for DFS
Functional limb preservation between infection control, vascular medicine and resurfacing
- Interstitial Lung Diseases
Update on Idiopathic Pulmonary Fibrosis
- Ischemic stroke: Are smaller or larger brain arteries affected?